# A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.

> **NCT01290718** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 4 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** capecitabine [Xeloda]
- **DRUG:** trastuzumab [Herceptin]

## Key facts

- **NCT ID:** NCT01290718
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2014-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01290718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01290718, "A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01290718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*